title: Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis.
abstract: OBJECTIVE
  To determine if mastectomy (Mx) use, chemotherapy (CT) intensity, or treatment sequence of CT, radiation therapy (RT), and Mx have improved outcome for inflammatory breast cancer (IBC).
  
  
  METHODS
  A retrospective analysis of 485 patients with IBC diagnosed in British Columbia between 1980 and 2000 analyzed locoregional relapse-free survival (LRFS) and breast cancer-specific survival (BCSS) by treatment intent and treatment received. Curative intent was defined as delivery of more than four cycles of anthracycline-based CT plus locoregional RT in patients without distant metastases.
  
  
  RESULTS
  Median follow-up among survivors was 6.5 years. Median BCSS was 1.0 and 3.2 years for patients with distant metastases at diagnosis or those who were curatively treated, respectively. Among patients treated curatively (n = 308), there were no significant differences in LRFS or BCSS with timing of Mx before or after CT/RT, time between diagnosis and RT, or the sequence of RT and CT. Patients receiving more intensive CT had improved 10-year BCSS compared with standard CT (43.7% v 26.3%; P = .04). Ten-year LRFS for patients having Mx after CT, Mx before CT, and without Mx was 62.8%, 58.6%, and 34.4%, respectively (P = .0001); the corresponding 10-year BCSS was 36.9%, 19.9%, and 22.5%, respectively (P = .005). On multivariate analysis, Mx was associated with improved LRFS (P = .04). Independent prognostic factors for BCSS were menopausal status (P = .02), estrogen receptor status (P = .02), and CT type (P = .05).
  
  
  CONCLUSIONS
  This retrospective analysis suggested that mastectomy, in conjunction with CT and RT, seemed to enhance locoregional control, whereas modern CT regimens seemed to improve BCSS.
authors.affiliation: Breast Cancer Outcomes Unit, BC Cancer Agency-Vancouver Island Centre, 2410 Lee Avenue, Victoria, BC, Canada.
authors.forename: Miguel
authors.initials: M
authors.lastname: Panades
authors.forename: Ivo A
authors.initials: IA
authors.lastname: Olivotto
authors.forename: Caroline H
authors.initials: CH
authors.lastname: Speers
authors.forename: Tamara
authors.initials: T
authors.lastname: Shenkier
authors.forename: Theodora A
authors.initials: TA
authors.lastname: Olivotto
authors.forename: Lorna
authors.initials: L
authors.lastname: Weir
authors.forename: Sharon J
authors.initials: SJ
authors.lastname: Allan
authors.forename: Pauline T
authors.initials: PT
authors.lastname: Truong
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D001955:British Columbia; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D011159:Population Surveillance / Q000379:methods*; D011379:Prognosis; D011878:Radiotherapy; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents